SCHEMBL30984268

SCHEMBL30984268

CC1(Oc2ncnc(NCCc3ccccn3)c2N)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 2/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ RAB9A P51151 2/20 0.48
▸ CYP1A2 P05177 2/20 0.42
▸ AURKA O14965 1/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ PGK1 P00558 1/20 0.41
▸ HRH3 Q9Y5N1 1/20 0.41
▸ ALDH1A1 P00352 3/20 0.40
▸ LMNA P02545 2/20 0.40
▸ TAAR1 Q96RJ0 1/20 0.40
▸ ALOX15 P16050 1/20 0.40
▸ POLB P06746 1/20 0.38
▸ PKM P14618 1/20 0.38
▸ APP P05067 2/20 0.38
▸ TLR8 Q9NR97 1/20 0.38
▸ TLR7 Q9NYK1 1/20 0.38
▸ EGFR P00533 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ HIF1A Q16665 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30983996 0.85 MAPK1 (0.46) HTTSMN1; SMN2RAB9ANPC1ALDH1A1
SCHEMBL30983967 0.84 RECQL (0.42) HTTSMN1; SMN2RAB9AAURKANPC1
SCHEMBL30983842 0.81 KDM4C (0.46) HTTSMN1; SMN2RAB9ANPC1LMNA
SCHEMBL31269125 0.81 PDE10A (0.36) HTTSMN1; SMN2RAB9ACYP1A2ALDH1A1
SCHEMBL30983865 0.78 EGFR (0.44) HTTSMN1; SMN2RAB9AAURKALMNA
SCHEMBL30984026 0.74 TAAR1 (0.38) AURKANPC1TAAR1POLBGALR3
SCHEMBL30984051 0.74 TAAR1 (0.38) AURKANPC1TAAR1POLBGALR3
SCHEMBL31321978 0.74 TAAR1 (0.38) AURKANPC1TAAR1POLBGALR3
SCHEMBL30983918 0.70 MAPK1 (0.49) HTTSMN1; SMN2APPEGFR
SCHEMBL17803699 0.67 HTT (0.67) HTTSMN1; SMN2RAB9ACYP1A2AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO disclosed
Send feedback